CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Immunology

• Publication date

  2006-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CLIM.2006.05.006PMID 16797237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.

  2005cited by this paper
• Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.

  2005cited by this paper
• Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.

  2004cited by this paper
• Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity.

  2004cited by this paper
• Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis

  2004cited by this paper
• IL-10-Secreting Regulatory T Cells Do Not Express Foxp3 but Have Comparable Regulatory Function to Naturally Occurring CD4+CD25+ Regulatory T Cells 1

  2004cited by this paper
• In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes

  2004cited by this paper
• Induction of FOXP3‐expressing regulatory CD4pos T cells by human mature autologous dendritic cells

  2004cited by this paper
• Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells

  2004cited by this paper
• Natural and Induced CD4+CD25+ Cells Educate CD4+CD25− Cells to Develop Suppressive Activity: The Role of IL-2, TGF-β, and IL-101

  2004cited by this paper
• Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7

  2004cited by this paper
• In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

  2004cited by this paper
• Frontline: Neuropilin‐1: a surface marker of regulatory T cells

  2004cited by this paper
• Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3

  2003cited by this paper
• Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype

  2003cited by this paper
• Supporting Online Material

  2003cited by this paper
• Cutting Edge: Cure of Colitis by CD4+CD25+ Regulatory T Cells1

  2003cited by this paper
• An essential role for Scurfin in CD4+CD25+ T regulatory cells

  2003cited by this paper
• Tolerogenic dendritic cells.

  2003cited by this paper
• Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

  2003cited by this paper
• CD25+ Immunoregulatory CD4 T Cells Mediate Acquired Central Transplantation Tolerance1

  2003cited by this paper
• CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

  2003cited by this paper
• CD4+CD25+ and CD4+CD25− T Cells Act Respectively as Inducer and Effector T Suppressor Cells in Superantigen-Induced Tolerance1

  2003cited by this paper
• Regulatory lymphocytes: Regulatory T cells in transplantation tolerance

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation

  2002cited by this paper
• Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells.

  2002cited by this paper
• EncephalomyelitisExperimental Autoimmune System Inflammation During Active Immune Responses and Central Nervous Cells Suppress Antigen-Specific Autoreactive Regulatory T + CD25+ Cutting Edge: CD4

  2002cited by this paper
• CD4+CD25+ Immunoregulatory T Cells

  2002cited by this paper
• The Subpopulation of CD4+CD25+ Splenocytes That Delays Adoptive Transfer of Diabetes Expresses L-Selectin and High Levels of CCR71

  2002cited by this paper
• Alemtuzumab in stem cell transplantation

  2002cited by this paper
• A Novel Costimulation Pathway Via the 4C8 Antigen for the Induction of CD4+ Regulatory T Cells1

  2002cited by this paper
• Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function

  2001cited by this paper
• The CD52 antigen and development of the CAMPATH antibodies.

  2001cited by this paper
• IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells.

  2001cited by this paper
• Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood

  2001cited by this paper
• IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells1

  2001cited by this paper
• Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells

  2001cited by this paper
• CD4(+) regulatory T cells.

  2001cited by this paper
• Regulating the immune response to transplants. a role for CD4+ regulatory cells?

  2001cited by this paper
• Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood

  2001cited by this paper
• Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders

  2001cited by this paper
• Differentiation of Regulatory T Cells 1 Is Induced by CD2 Costimulation1

  2001cited by this paper
• Type 1 T regulatory cells

  2001cited by this paper
• Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice

  2000cited by this paper
• Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

  2000cited by this paper
• The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.

  2000cited by this paper
• Characterization of the 4C8 Antigen Involved in Transendothelial Migration of CD26hi T Cells after Tight Adhesion to Human Umbilical Vein Endothelial Cell Monolayers

  1999cited by this paper
• Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle.

  1999cited by this paper
• Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

  1999cited by this paper
• Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

  1999cited by this paper
• Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

  1999cited by this paper
• Mechanism of Interleukin-10 Inhibition of T-Helper Cell Activation by Superantigen at the Level of the Cell Cycle

  1999cited by this paper
• Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells

  1998cited by this paper
• A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

  1997cited by this paper
• Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

  1997cited by this paper
• Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils.

  1996cited by this paper
• CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.

  1996cited by this paper
• Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.

  1995cited by this paper
• Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

  1995cited by this paper
• CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.

  1995cited by this paper
• A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes.

  1995cited by this paper
• Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases.

  1994cited by this paper
• A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone

  1993cited by this paper
• Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice

  1993cited by this paper
• Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

  1991cited by this paper
• The staphylococcal enterotoxins and their relatives.

  1990cited by this paper
• V beta-specific stimulation of human T cells by staphylococcal toxins.

  1989cited by this paper
• Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.

  1983cited by this paper
• Selective extraction of polyoma DNA from infected mouse cell cultures.

  1967cited by this paper

• Investigation of hub-shared genes and regulatory mechanisms of rheumatoid arthritis and atherosclerosis

  2025cites this paper
• UPF1 attenuates CD8+ T cell exhaustion in glioma by destabilizing CD52 mRNA.

  2025cites this paper
• Targeting Impaired Type I Interferon–IL-27 Signaling Rescues T Regulatory Cell Suppressive Function in Relapsing-Remitting Multiple Sclerosis

  2025influential citation
• From Multiple Sclerosis to Organ-Specific Autoimmune Disorders: Insights into the Molecular and Clinical Implications of Comorbidity

  2024cites this paper
• Status of islet transplantation and innovations to sustainable outcomes: novel sites, cell sources, and drug delivery strategies

  2024cites this paper
• Cis-interaction between CD52 and T cell receptor complex interferes with CD4+ T cell activation in acute decompensation of cirrhosis

  2024cites this paper
• Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

  2024cites this paper
• CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma

  2023cites this paper
• The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives

  2023cites this paper
• Single-cell RNA-Seq identifies precise tolerogenic cellular and molecular pathways induced by depigmented-polymerized grass pollen allergen extract.

  2023cites this paper
• Single cell epigenomic and transcriptomic analysis uncovers potential transcription factors regulating mitotic/meiotic switch

  2023cites this paper
• 靶向CD52嵌合抗原受体T细胞的制备及其抗白血病作用研究

  2022cites this paper
• CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

  2022cites this paper
• T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development

  2022cites this paper
• Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning

  2022cites this paper
• Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

  2022cites this paper
• Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management

  2022cites this paper
• Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis

  2021cites this paper
• Cancer immunotherapy from biology to nanomedicine.

  2021cites this paper
• Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era

  2021cites this paper
• Allergen-Specific Treg Cells Upregulated by Lung-Stage S. japonicum Infection Alleviates Allergic Airway Inflammation

  2021cites this paper
• Regulatory T Cells for the Induction of Transplantation Tolerance.

  2021cites this paper
• Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models.

  2021cites this paper
• Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double negative T cells and newly generated T and B cells.

  2020cites this paper
• Novel targeted therapies of T cell lymphomas

  2020cites this paper
• Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia

  2020cites this paper
• CD52+ regulatory T cells and CD52-expressing sperms downregulated in couples with unexplained infertility: A case–control study

  2020cites this paper
• Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System

  2020influential citation
• The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis

  2020cites this paper
• CD52‐negative T cells predict acute graft‐versus‐host disease after an alemtuzumab‐based conditioning regimen

  2020cites this paper
• Bioinformatics Analysis of Microarray Datasets to Identify Prognostic Factors in Lung Adenocarcinoma

  2020cites this paper
• Allergen specific Treg upregulated by lung-stage schistosome infection alleviates allergic airway inflammation via inhibiting IgE secretion

  2020cites this paper
• Advances in targeted therapy for malignant lymphoma

  2020cites this paper
• Current Development of Monoclonal Antibodies in Cancer Therapy.

  2020cites this paper
• The inflammasome of circulatory collapse: single cell analysis of survival on extracorporeal life support

  2019cites this paper
• The local immune response in melanoma. In situ analysis of the micro-environmental immune-signature of primary melanoma.

  2018cites this paper
• Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility

  2018cites this paper
• Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients

  2018cites this paper
• Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis

  2018cites this paper
• Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation

  2017cites this paper
• Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia

  2017cites this paper
• Mechanism of action of three newly registered drugs for multiple sclerosis treatment

  2017cites this paper
• Alemtuzumab for multiple sclerosis: the new concept of immunomodulation

  2017cites this paper
• The immunological function of CD52 and its targeting in organ transplantation

  2017cites this paper
• The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease

  2017cites this paper
• Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

  2016cites this paper
• Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab

  2016cites this paper
• Open Peer Review

  2016cites this paper
• Genetics and immunity in the era of single-cell genomics

  2016cites this paper
• Impact of Immune-Modulatory Drugs on Regulatory T Cell

  2016cites this paper
• Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.

  2016cites this paper
• The right running head: EXPRESSION PROFILING OF HUMAN TH17 DIFFERENTIATION

  2016cites this paper
• A review of monoclonal antibody therapies in lymphoma.

  2016cites this paper
• New Strategies in Multiple Sclerosis Therapy International Journal of Autoimmune Disorders & Therapy

  2016cites this paper
• THERAPY OF ENDOCRINE DISEASE: Islet transplantation for type 1 diabetes: so close and yet so far away.

  2015cites this paper
• Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

  2015cites this paper
• Pharmacologic Targeting of Regulatory T Cells for Solid Organ Transplantation: Current and Future Prospects

  2015cites this paper
• Alemtuzumab for the treatment of multiple sclerosis

  2015cites this paper
• Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity

  2015cites this paper
• Multiple sclerosis - New treatment modalities

  2015cites this paper
• Regulatory T-Cell Therapy in Transplantation and Severe Autoimmunity.

  2015cites this paper
• Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications

  2015cites this paper
• Current status of antibody therapy in ALL

  2015cites this paper
• Erratum to: Pharmacologic Targeting of Regulatory T Cells for Solid Organ Transplantation: Current and Future Prospects

  2015cites this paper
• The Immunophysiology of Male Reproduction

  2014cites this paper
• Drug safety evaluation of alemtuzumab for multiple sclerosis

  2014cites this paper
• Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia

  2014cites this paper
• Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro

  2014cites this paper
• Understanding autoimmunity in the eye: from animal models to novel therapies.

  2014cites this paper
• Gut-adipose tissue axis in hepatic fat accumulation in humans.

  2014cites this paper
• Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety

  2014cites this paper
• Influence of pharmacological immunomodulatory agents on CD4CD25FoxP3 T regulatory cells in humans☆

  2013cites this paper
• Clinical application of regulatory T cells in type 1 diabetes

  2013cites this paper
• The Outlook for Alemtuzumab in Multiple Sclerosis

  2013cites this paper
• Drugs in Development for Relapsing Multiple Sclerosis

  2013cites this paper
• T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10

  2013cites this paper
• CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells

  2013cites this paper
• Emerging molecular therapies for the treatment of acute lymphoblastic leukemia.

  2013cites this paper
• Influence of pharmacological immunomodulatory agents on CD4(+)CD25(high)FoxP3(+) T regulatory cells in humans.

  2013cites this paper
• Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.

  2013cites this paper
• Immune status following alemtuzumab treatment in human CD52 transgenic mice.

  2013cites this paper
• Global identification of genes and pathways regulated by Akt during activation of T helper cells

  2013cites this paper
• Immune regulation by CD52-expressing CD4 T cells

  2013cites this paper
• regulatory cells in humans

  2013cites this paper
• Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

  2013cites this paper
• Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas

  2013cites this paper
• Regulatory T-cells for immunotherapy

  2013cites this paper
• Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?

  2013cites this paper
• The Effects of Immunosuppression on Regulatory CD4+CD25+ T Cells

  2012cites this paper
• Identification of early gene expression changes during human Th17 cell differentiation.

  2012cites this paper
• Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes

  2012cites this paper
• A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease

  2012cites this paper
• The N-linked carbohydrate moiety of male reproductive tract CD52 (mrt-CD52) interferes with the complement system via binding to C1q.

  2012cites this paper
• Antibody Therapy for Acute Lymphoblastic Leukemia

  2012cites this paper
• Investigation of the lymphocyte function during tubulointerstitial injury in the native kidney

  2012cites this paper
• A study of regulatory T cells in allogeneic haematopoietic stem cell transplantation

  2012cites this paper
• T cell subsets and the outcome of haematopoietic stem cell transplantation

  2012cites this paper
• Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation

  2012cites this paper
• Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

  2012cites this paper
• Emerging strategies for the treatment of multiple sclerosis

  2012cites this paper